

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 September 2020 (24.09.2020)



(10) International Publication Number
WO 2020/190754 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 491/18 (2006.01)
C07D 471/04 (2006.01) C07D 491/22 (2006.01)

(21) International Application Number:

PCT/US2020/022724

(22) International Filing Date:

13 March 2020 (13.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/819,064 15 March 2019 (15.03.2019) US

(71) Applicant: **FULCRUM THERAPEUTICS, INC.**
[US/US]; 26 Landsdowne Street, Cambridge, Massachu-
setts 02139 (US).

(72) Inventors: **EFREMOV, Ivan Viktorovich**; 83 Payson
Rd., Chestnut Hill, Massachusetts 02467 (US). **KAZMIRSKI, Steven**; 18 Forest Street, Sherborn, Mass-
achusetts 01770 (US). **LI, Qingyi**; 419 Norfolk Street,
Apt 2E, Somerville, Massachusetts 02143 (US). **THOM-
PSON, III, Lorin A.**; 20 Short Street, Cohasset, Massa-
chusetts 02025 (US). **WALLACE, Owen Brendan**; 160
Salisbury Road, Brookline, Massachusetts 02445 (US). **JOHNSTONE, Shawn Donald**; 1600 rue de Beauvoir,
Saint-Lazare, Québec J7T 0B1 (CA). **ZHOU, Feng**; 15 rue
Pasteur, Dollard-des-Ormeaux, Québec H9A 1M1 (CA). **RAHL, Peter**; 43 Eliot St., Natick, Massachusetts 01760
(US).

(74) Agent: **CHRISTIANSEN, William T. et al.**; Cooley LLP,
1299 Pennsylvania Avenue, NW, Suite 700, Washington,
District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS



(57) Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X₁, X₂, X₃, A₁, A₂, Y, R₁, R₂, R₃, and R₄ are as described herein.

WO 2020/190754 A1